Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia
Saurabh Zanwar,Jennifer Le-Rademacher,Eric Durot,Shirley D’Sa,Jithma P. Abeykoon,Patrizia Mondello,Shaji Kumar,Shayna Sarosiek,Jonas Paludo,Saurabh Chhabra,Joselle M. Cook,Ricardo Parrondo,Angela Dispenzieri,Wilson I. Gonsalves,Eli Muchtar,Sikandar Ailawadhi,Robert A. Kyle,S. Vincent Rajkumar,Alain Delmer,Rafael Fonseca,Morie A. Gertz,Steven P. Treon,Stephen M. Ansell,Jorge J. Castillo,Prashant Kapoor
DOI: https://doi.org/10.1200/jco.23.02066
IF: 45.3
2024-05-26
Journal of Clinical Oncology
Abstract:PURPOSE Patients with Waldenström macroglobulinemia (WM) have disparate outcomes. Newer therapies have emerged since the development of International Prognostic Scoring System, and MYD88 L265P mutation is now frequently assessed at diagnosis, warranting reexamination of the prognostic parameters. PATIENTS AND METHODS We reviewed records of 889 treatment-naïve patients with active WM, consecutively seen between January 01, 1996, and December 31, 2017, to identify clinical predictors of overall survival (OS) in univariate analyses. Patients with complete data for the parameters significant on the univariate analyses (n = 341) were included in a multivariable analysis to derive a prognostic model, subsequently validated in a multi-institutional cohort. RESULTS In the derivation cohort (n = 341), age (hazard ratio [HR], 1.9 [95% CI, 1.2 to 2.1]; P = .0009), serum lactate dehydrogenase (LDH) above upper limit of normal (HR, 2.3 [95% CI, 1.3 to 4.5]; P = .007), and serum albumin <3.5 g/dL (HR, 1.5 [95% CI, 0.99 to 2.3]; P = .056) were independently prognostic. By assigning a score of 1 point each to albumin 75 years (HR, 2.6) or elevated LDH (HR, 2.3), four groups with distinct outcomes were observed on the basis of the composite scores. Five-year OS was 93% for the low-risk (score 0), 82% for low-intermediate risk (score 1), 69% for intermediate-risk (score 2), and 55% for the high-risk (score ≥3; P < .0001) groups. In the validation cohort (N = 335), the model maintained its prognostic value, with a 5-year OS of 93%, 90%, 75%, and 57% for the four groups, respectively ( P < .0001). CONCLUSION Modified Staging System for WM (MSS-WM), utilizing age, albumin, and LDH is a simple, clinically useful, and externally validated prognostic model that reliably risk-stratifies patients with symptomatic WM into four groups with distinct prognosis.
oncology